|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 11-18 | Panacea Life Sciences Holdings and Benivita Inc. Launch Benivita PLSH | CI |
| 06/05/24 | Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Market Cap | 519K 447K 412K 387K 726K 49.07M 734K 4.87M 1.9M 24.03M 1.95M 1.91M 83.27M | P/E Ratio 2022 |
-0.11x | P/E Ratio 2023 | -0.31x |
|---|---|---|---|---|---|
| Enterprise Value | 22.05M 19M 17.5M 16.43M 30.84M 2.08B 31.17M 207M 80.55M 1.02B 82.75M 80.99M 3.54B | EV / Sales 2022 |
11.6x | EV / Sales 2023 | 10.1x |
| Free-Float |
-
| Yield 2022 * |
-
| Yield 2023 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.61% | -1.94% | +39.00% | +150.72% | 1,007B | ||
| -0.20% | -0.77% | +51.51% | +43.20% | 567B | ||
| +0.40% | -1.31% | +16.56% | +60.47% | 392B | ||
| -0.80% | +1.05% | +20.91% | +18.37% | 328B | ||
| -0.43% | +2.01% | +23.20% | +32.46% | 277B | ||
| +0.64% | -3.71% | +20.92% | +13.67% | 275B | ||
| -1.86% | +3.05% | -45.70% | -49.24% | 196B | ||
| -0.77% | +0.95% | +17.69% | +51.46% | 189B | ||
| +2.36% | +1.38% | +14.80% | +61.34% | 154B | ||
| Average | -0.05% | +0.33% | +17.65% | +42.49% | 376.23B | |
| Weighted average by Cap. | -0.25% | -0.03% | +26.78% | +67.42% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 1.63M 1.4M 1.29M 1.21M 2.28M 154M 2.3M 15.26M 5.94M 75.33M 6.11M 5.98M 261M | 2.38M 2.06M 1.89M 1.78M 3.34M 225M 3.37M 22.36M 8.71M 110M 8.95M 8.76M 383M |
| Net income | -9.14M -7.88M -7.26M -6.81M -12.79M -864M -12.92M -85.73M -33.4M -423M -34.31M -33.58M -1.47B | -8.02M -6.91M -6.36M -5.97M -11.21M -758M -11.33M -75.16M -29.28M -371M -30.08M -29.44M -1.29B |
| Net Debt | 17.85M 15.39M 14.17M 13.3M 24.98M 1.69B 25.24M 167M 65.22M 827M 67M 65.58M 2.86B | 21.53M 18.55M 17.09M 16.04M 30.12M 2.04B 30.44M 202M 78.65M 997M 80.8M 79.08M 3.45B |
Employees
-
Sector
Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
















